Nuvo Pharmaceuticals Inc MRVFF

Reality Check

[consultant99]

I only venture back periodically after essentually selling almost all of my shares within the last two years. We fought unsuccssfully against the spin-off of Crescita when the share price was at $6.65

Since then the two enterprises have lost 64% of their value - $4.25/share!! BB has been intimately involved with Nuvo over the years and provided a positive opinion used by management to help sell the spin-off so keep that in mind when looking at their forecasted share price.

Jesse has taken a huge risk in acquiring the assets and I sincerely hope he is successful in turning Nuvo around - I know some long-suffering shareholders who deserve a break.

I still keep in touch with fellow investors that sold NRI and have moved on to a company called Theralase TLT. They successfully completed a phase 1 trial on bladder cancer and are now starting their phase 2 at Princess Margaret Hospital in Toronto. I have been in this company for a number of years and find it a compelling story. I have stopped recommending stocks on bulleton boards so do your own due diligence on this one.

There is a chance the stock can rise substantially from here if management can pull this off - worth hanging around for a quarter or two to see how they make out if you already own shares.

[Cubalibra]

This post has been removed in accordance with Community Policy

[lscfa]

Vimovo sales in the US were 15% of total sales for this latest quarter and the co. will not lose all of that any time soon to generics. The stock price has crashed 40%. Disconnect.  

[Marathon11]

Yes. Manipulation by so-called pros. News on patents, although relatively minor, is a great excuse to shake the tree and accumulate from those less informed. Try and scare-out retail shares or force margin calls. I have to buy a bit more at these levels. Just my opinions of course. Always great to hear from you C99. I have also been buying some V.TLT on your reco.

[runmyownlife]

It only took 110,000 shares to cause the 40% drop. That's an indication of too few interested buyers rather than an indictment of the financial situation. I'd argue management's seemingly perpetual slow execution, particularly in sales and market development, along with very limited promotion are greater cause for concern than the court case. Executive renumeration should be more

[Marathon11]

Can't disagree with any of that. Weak sense of urgency and track record of missed milestones and inability to drive shareholder value. I am hopeful that Jesse and the new Chair of the BOD can change the game in conjunction with this major acquisition. Hopefully the rest of the BOD will be changed out sooner rather than later. They need institutional coverage... essentially they have none as I